Physician profile
Paul A Maertens
NPI 1912951195
$9,697.27
in general payments reported to CMS, 2019-2025
60 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $501 · 2021: $2,986 · 2022: $1,575 · 2023: $1,346 · 2024: $1,098 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,359.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,754.33 | 2019-2023 | Qelbree |
| Ucb, INC. | $1,065.45 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $482.42 | 2022-2024 | Epidiolex |
| Sunovion Pharmaceuticals INC. | $448.79 | 2019-2022 | |
| Sk Life Science, INC. | $445.62 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $389.80 | 2021-2025 | Nuplazid, Daybue |
| Biogen, INC. | $387.99 | 2019-2022 | |
| Neurelis, INC. | $303.53 | 2020-2025 | Valtoco |
| Genentech USA, INC. | $285.22 | 2022-2024 | Ocrevus, Enspryng, Evrysdi |
| Upsher-Smith Laboratories LLC | $265.25 | 2021-2025 | |
| Eisai INC. | $257.68 | 2019-2023 | |
| Acorda Therapeutics, INC | $174.45 | 2019-2024 | Inbrija |
| Sanofi-Aventis U.S. LLC | $144.88 | 2025 | |
| Emd Serono, INC. | $126.54 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $124.98 | 2021 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Maertens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.